{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-26-000040","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.389209+00:00","generated_at":"2026-05-14T22:05:53.486641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M","bullets":["Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.","Net loss $0.5M vs $102.6M loss in Q1 2025; positive Adj. EBITDA $26.2M.","Completed ~52,800 clinical cases (+15% YoY); reaffirms FY2026 revenue guidance $1.0-$1.02B.","Free cash flow positive $22.5M, inclusive of $30.5M annual bonus payments.","Launched MolDX-approved Caris ChromoSeq; refinanced $400M credit facility with Blue Owl/Blackstone."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-26-000040","json":"https://secwatch.observer/filing/0002019410-26-000040.json","markdown":"https://secwatch.observer/filing/0002019410-26-000040.md","text":"https://secwatch.observer/filing/0002019410-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/cai-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:05:53.486641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"817f28728e78b072be993fa612f4c5d36d1c235e","claim":"Caris Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue Total revenue was $216.2 million, net income Net loss was $0.5 million, EPS Net loss per share attributable to common shareholders, basic and diluted, was $0.00. Guidance reaffirmed.","evidence_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001062993-26-002965","ticker":"HIVE","company_name":"HIVE Digital Technologies Ltd.","filed_at":"2026-06-02T10:23:19+00:00","headline":"HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002965","json":"https://secwatch.observer/filing/0001062993-26-002965.json","markdown":"https://secwatch.observer/filing/0001062993-26-002965.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/form8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm"}},{"accession":"0000029644-26-000049","ticker":"DCI","company_name":"DONALDSON Co INC","filed_at":"2026-06-01T21:41:36+00:00","headline":"Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029644-26-000049","json":"https://secwatch.observer/filing/0000029644-26-000049.json","markdown":"https://secwatch.observer/filing/0000029644-26-000049.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/dci-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"press release is furnished herewith as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nDonaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm"}},{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}},{"accession":"0001628280-26-039474","ticker":"CRDO","company_name":"Credo Technology Group Holding Ltd","filed_at":"2026-06-01T20:08:16+00:00","headline":"Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs","event_type":"earnings","sec_items":["2.02","5.02","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039474","json":"https://secwatch.observer/filing/0001628280-26-039474.json","markdown":"https://secwatch.observer/filing/0001628280-26-039474.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/0001628280-26-039474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/crdo-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"On June 1, 2026, Credo Technology Group Holding Ltd (the \"Company\") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807794/000162828026039474/0001628280-26-039474-index.htm"}},{"accession":"0001628280-26-039379","ticker":null,"company_name":"DAVEY TREE EXPERT CO","filed_at":"2026-06-01T17:50:11+00:00","headline":"Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039379","json":"https://secwatch.observer/filing/0001628280-26-039379.json","markdown":"https://secwatch.observer/filing/0001628280-26-039379.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/davey-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"Exchange Act, unless such subsequent filing specifically references this Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nTo Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm"}},{"accession":"0000029332-26-000027","ticker":"DXYN","company_name":"DIXIE GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029332-26-000027","json":"https://secwatch.observer/filing/0000029332-26-000027.json","markdown":"https://secwatch.observer/filing/0000029332-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/dxyn-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}},{"accession":"0001104659-26-058180","ticker":"URG","company_name":"UR-ENERGY INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058180","json":"https://secwatch.observer/filing/0001104659-26-058180.json","markdown":"https://secwatch.observer/filing/0001104659-26-058180.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/0001104659-26-058180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/urg-20260508x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%. The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions. Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively. Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/0002019410-26-000040-index.htm","comparable_excerpt":"a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1375205/000110465926058180/0001104659-26-058180-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}